Analyst Price Targets — NRXS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 22, 2025 2:28 pm | — | Craig-Hallum | $8.00 | $3.39 | TheFly | Neuraxis price target raised to $8 from $7 at Craig-Hallum |
| June 16, 2025 11:28 am | Chase Knickerbocker | Craig-Hallum | $7.00 | $2.52 | TheFly | Neuraxis initiated with a Buy at Craig-Hallum |
Latest News for NRXS
NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.
NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage…
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NRXS.
U.S. House Trading
No House trades found for NRXS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.